Systematic Reviews
Copyright ©The Author(s) 2021.
World J Gastrointest Oncol. Nov 15, 2021; 13(11): 1813-1832
Published online Nov 15, 2021. doi: 10.4251/wjgo.v13.i11.1813
Table 2 Baseline characteristics of patients among the included studies
Finn et al[12], 2020
Lee et al[16], 2020

Interventional arm
Control arm
Interventional arm
Control arm
Atezolizumab-bevacizumab combination therapy
Sorafenib monotherapy
Atezolizumab-bevacizumab combination therapy given in both Arms A and F
Atezolizumab monotherapy
Group A
Group F+
n = 336
n = 165
n = 104
n = 60
n = 59
Median age (IQR), yr64 (56-71)66 (59-71)62 (23-82)60 (22-82)63 (23-85)
Gender, n (%)
Male277 (82)137 (83)84 (81)54 (90)49 (83)
Female59 (18)28 (17)20 (19)6 (10)10 (17)
Race, n (%)
White123 (37)52 (32)20 (19)14 (23)9 (15)
Asian188 (56)96 (58)75 (72)45 (75)47 (80)
Black or African American6 (1.8)4 (2.4)7 (7)1 (2)2 (3)
Native Hawaiian or other Pacific Islander0 (0)0 (0)0 (0)0 (0)1 (2)
Unknown19 (6)12 (7)2 (2)0 (0)0 (0)
Geographic region, n (%)
Asian excluding Japan133 (40)68 (41)59 (57)39 (65)39 (66)
Rest of the world (United States, Australia, New Zealand, and Japan)203 (60)97 (59)45 (43)21 (35)20 (34)
Child Pugh, n (%)
Child Pugh A5239 (72)121 (73)77 (74)43 (72)42 (71)
Child Pugh A694 (28)44 (27)21 (20)17 (28)17 (29)
Child Pugh A70 (0)06 (6)17 (28)17 (29)
Child Pugh B1 (< 1)0 (0)NANANA
ECOG performance status, n (%)
ECOG 0209 (62)103 (62)52 (50)27 (45)25 (42)
ECOG 1127 (38)62 (38)52 (50)33 (55)34 (58)
BCLC, n (%)
BCLC stage A (early)8 (2)6 (4)0 (0)0 (0)2 (3)
BCLC stage B (intermediate)52 (15)26 (16)10 (10)6 (10)4 (7)
BCLC stage C (advanced)276 (82)133 (81)94 (90)54 (90)53 (90)
Alpha-fetoprotein > 400 ng per milliliter 126 (38%)61 (37%)37 (36%)18 (30%)19 (32%)
Macrovascular invasion129 (38%)71 (43%)55 (53%)20 (33%)25 (42%)
Extrahepatic spread212 (63%)93 (56%)91 (88%)47 (78%)50 (85%)
Hepatitis B164 (49%)76 (46%)51 (49%)34 (57%)32 (54%)
Hepatitis C72 (21%)36 (22%)31 (30%)11 (18%)10 (17%)
Non-viral100 (30%)85 (52%)22 (21%)15 (25%)17 (29%)
Alcohol use, n (%)
Previous166 (50)79 (48)58 (56)39 (65)32 (54)
Never121 (36)61 (37)32 (31)14 (23)21 (36)
Current48 (14)25 (15)14 (13)7 (12)6 (10)
Varices at baseline88 (26%)43 (26%)NANANA
Varices treated at baseline36 (11%)23 (14%)NANANA
PD-L1 status, n (%)12458NANANA
TC and IC < 1% 45 (36) 25 (43)25 (24)15 (25)18 (31)
TC or IC ≥ 1% 79 (64) 33 (57) 61 (59)28 (47)34 (58)
TC ≥ 5% or IC ≥ 5% 46 (37) 17 (29)37 (36)8 (13)16 (27)
TC ≥ 10% or IC ≥ 10% 12 (10) 5 (9)30 (29)5 (8)6 (10)
Data missingNANA18 (17)17 (28)8 (14)
Prior local therapy for HCC, n (%)
At least one treatment161 (48) 85 (52)NANANA
Transarterial chemoembolization 130 (39)70 (42) NANANA
Radiofrequency ablation47 (14) 24 (15) NANANA
Prior radiotherapy 34 (10) 17 (10) NANANA